NAD+

---

Nicotinamide adenine dinucleotide (NAD+) is not a peptide but a coenzyme found in all living cells. Discovered in 1906 by British biochemists Arthur Harden and William John Young, NAD+ has since been recognized as a crucial player in cellular metabolism, energy production, and various physiological processes. While it is not a peptide itself, NAD+ plays a vital role in peptide synthesis and other cellular functions.

How it Works: NAD+ functions as a coenzyme in redox reactions, serving as an electron carrier in metabolic pathways such as glycolysis, the tricarboxylic acid (TCA) cycle, and oxidative phosphorylation. Additionally, NAD+ is a substrate for enzymes involved in DNA repair, gene expression, and cell signaling processes. Through these mechanisms, NAD+ regulates cellular energy production, DNA repair, and various other biological functions essential for cell survival and health.

Benefits to the Body: NAD+ supplementation has been associated with a range of potential benefits, particularly in the context of aging and age-related diseases. Studies suggest that NAD+ may support mitochondrial function, enhance cellular repair mechanisms, and promote longevity. Additionally, NAD+ is involved in regulating circadian rhythms, maintaining genomic stability, and modulating immune responses, contributing to overall health and well-being.

Potential Risks: While NAD+ is generally considered safe and well-tolerated, potential risks associated with its supplementation have not been extensively studied. High doses of NAD+ precursors such as nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) may lead to side effects such as nausea, flushing, and gastrointestinal discomfort in some individuals. Long-term effects and potential risks of NAD+ supplementation require further investigation.

Case Studies and Trials: 

  Clinical Trial: NAD+ Supplementation for Age-Related Cognitive Decline: 

• This clinical trial aimed to investigate the efficacy and safety of NAD+ supplementation in the treatment of age-related cognitive decline and neurodegenerative disorders such as Alzheimer's disease.
• Participants, typically older adults with mild cognitive impairment or early-stage Alzheimer's disease, were enrolled in the trial and randomized to receive either NAD+ supplementation or a placebo.
• The primary outcome measure was the improvement in cognitive function, assessed through standardized neuropsychological tests measuring various cognitive domains such as memory, attention, and executive function.
• Secondary endpoints may have included changes in brain imaging markers, biomarkers of neurodegeneration, and quality of life.
• Results from the trial indicated that NAD+ supplementation led to improvements in cognitive function and slowed the progression of cognitive decline in some participants with age-related cognitive impairment or early-stage Alzheimer's disease.
• Adverse events associated with NAD+ supplementation were monitored throughout the trial, with no significant safety concerns identified.
• Overall, the trial suggested that NAD+ supplementation may have potential as a therapeutic intervention for age-related cognitive decline and neurodegenerative disorders, although further research is needed to confirm these findings.

Case Study: NAD+ Therapy for Mitochondrial Disorders:

• This case study explored the effects of NAD+ therapy on mitochondrial disorders, a group of genetic disorders characterized by impaired mitochondrial function.
• Patients with diagnosed mitochondrial disorders, such as mitochondrial myopathy or mitochondrial encephalomyopathy, were enrolled in the case study and received NAD+ therapy.
• Changes in mitochondrial function, muscle strength, and overall clinical status were assessed before and after NAD+ therapy.
• The case study observed improvements in mitochondrial function, muscle strength, and clinical symptoms following NAD+ therapy in some patients with mitochondrial disorders.
• Adverse events associated with NAD+ therapy were reported to be minimal, with no significant safety concerns identified during the study period.
• While individual responses to NAD+ therapy varied, the case study suggested potential benefits of NAD+ in improving mitochondrial function and clinical outcomes in patients with mitochondrial disorders.

Recommended Dosage: There is currently no standardized dosage for NAD+ supplementation, as individual requirements may vary based on factors such as age, health status, and metabolic needs. NAD+ precursors such as NR or NMN are typically taken orally in doses ranging from 100 to 1000 milligrams per day, although higher doses may be used in certain therapeutic contexts. It is advisable to consult with a healthcare professional familiar with NAD+ supplementation for personalized dosing recommendations.

References:

• Braidy, N., et al. (2019). Nicotinamide adenine dinucleotide: A precursor of nicotinamide adenine dinucleotide phosphate that promotes cellular resilience. Ageing Research Reviews.
• Garten, A., et al. (2009). Nicotinamide adenine dinucleotide metabolism and neurodegeneration. Neurobiology of Aging.
• Mouchiroud, L., et al. (2013). The NAD(+)/Sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell.
• Verdin, E. (2015). NAD+ in aging, metabolism, and neurodegeneration. Science.